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Abstract 26	
The respiratory pathogen, Moraxella catarrhalis, is a human-specific commensal that 27	
frequently causes acute otitis media in children and stimulates acute exacerbations in 28	
chronic obstructive pulmonary disease (COPD) patients. The exact molecular 29	
mechanisms defining host-pathogen interactions promoting pathogenesis are not 30	
clearly understood. Limited knowledge hampers vaccine and immunotherapeutic 31	
development required to treat this emerging pathogen. Here we reveal in detail a 32	
novel antibacterial role displayed by short leucine–rich proteoglycans (SLRPs) in 33	
concert with complement. We show that fibromodulin (FMOD), osteoadherin 34	
(OSAD) and biglycan (BGN) but not decorin (DCN) enhance serum killing of M. 35	
catarrhalis. Our results suggests that M. catarrhalis binding to SLRPs is a conserved 36	
feature as the overwhelming majority of clinical and laboratory strains bound all four 37	
SLRPs. Furthermore, we resolve the binding mechanism responsible for this 38	
interaction and highlight the role of the ubiquitous surface protein (Usp), A2/A2H in 39	
mediating binding to host SLRPs.  A conserved immune evasive strategy used by M. 40	
catarrhalis and other pathogens is the surface acquisition of host complement 41	
inhibitors such as C4b-binding protein (C4BP). We observed that FMOD, OSAD and 42	
BGN competitively inhibit binding of C4BP to the surface of M. catarrhalis, resulting 43	
in increased C3b/iC3b deposition, membrane attack complex (MAC) formation and 44	
subsequently decreased bacterial survival. Furthermore, both OSAD and BGN 45	
promote enhanced neutrophil killing in vitro, both in a complement dependent and 46	
independent fashion. In summary, our results illustrate that SLRPs, FMOD, OSAD 47	
and BGN, portray complement-modulating activity enhancing M. catarrhalis killing, 48	
defining a new antibacterial role supplied by SLRPs.  49	 	  50	
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Introduction 51	
Evolutionary pressure has dictated the development of several key features to 52	
protect the mammalian host from infection from the billions of endogenous and 53	
exogenous microflora. The innate immune system governs the first response to any 54	
potentially infectious agent. Physical barriers lined with intricate detection and 55	
signaling systems, ancient elaborate effector pathways and responder phagocytic and 56	
antigen presenting cells mediate overall protection. One critical element of innate 57	
immunity in mediating this detection, response and subsequent elimination of foreign 58	
species is complement.  59	
The complement system is composed of a multitude of soluble or surface 60	
expressed proteins with defined activators and inhibitors embroiled in a constant flux 61	
to maintain homeostasis. Complement components circulate in the blood and 62	
extracellular fluids. Microbial activation of complement occurs through various 63	
means but converges at the level of C3 activated through the formation of C3 64	
convertases. These complexes instigate the cleavage of C3 into the anaphylatoxin and 65	
antimicrobial C3a peptide and major opsonin C3b/iC3b, responsible for mediating 66	
phagocytosis of foreign bodies by professional phagocytes. The next major step in 67	
complement activation is the formation of C5 convertases via binding of C3b to C3 68	
convertases resulting in a new enzymatic platform directing the cleavage of C5 into 69	
C5a and C5b. Whereas C5a is a potent anaphylatoxin, C5b deposits onto the bacterial 70	
membrane initiates the formation of the membrane attack complex, resulting in lysis 71	
of susceptible cells, such as Gram-negative bacteria (1). To prevent host cell attack, 72	
complement inhibitors regulate complement activation in a strict manner. Two soluble 73	
inhibitors, factor H (FH) and C4b-binding protein (C4BP) (2) prevent formation of C3 74	
convertase through binding of C3b and C4b respectively and serving as cofactors for 75	
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the serine protease, factor I.  76	
Microbes, particularly bacteria, have evolved several mechanisms to inhibit 77	
complement activation and examples of bacteria targeting every feature of 78	
complement have been reported (3). The Gram-negative opportunistic respiratory 79	
pathogen, Moraxella catarrhalis, is no exception. M. catarrhalis is a human specific 80	
commensal and a recognized respiratory pathogen (4, 5).  M. catarrhalis causes 81	
significant morbidity and economic burden as a common etiological agent of otitis 82	
media and exacerbations in patients with chronic obstructive pulmonary disease 83	
(COPD) (4, 5). One major immune evasion strategy employed by M. catarrhalis is 84	
the recruitment of the complement inhibitor C4BP (6). Inhibiting C4BP acquisition by 85	
M. catarrhalis may provide a novel therapeutic avenue to treat infections, which is 86	
urgently required given the increasing problem of failed therapy due to antibiotic 87	
resistance.  88	
Short-leucine rich proteoglycans (SLRPs) such as fibromodulin (FMOD), 89	
osteoadherin (OSAD), biglycan (BGN) and decorin (DCN) are extracellular matrix 90	
(ECM) components containing a distinct central leucine – rich repeat region (LRR) 91	
flanked by disulphide bridges at the N- and C-termini (7). SLRPs are highly versatile 92	
molecules displaying differences in glycosylation of the core region and amino acid 93	
sequence and charge at the terminal ends. Classically, SLRPs function as important 94	
components in maintaining and regulating the ECM structure and cellular adhesion 95	
through interaction with integrins (7). More recently, the role of SLRPs, specifically 96	
BGN and DCN, as regulators of the innate immune system in response to tissue injury 97	
or cellular stress has been illustrated. Under normal physiological conditions matrix-98	
bound SLRPs are not capable of immune activation, however in soluble form, 99	
following limited proteolysis of the ECM or secretion from macrophages, SLRPs act 100	
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as endogenous ligands of toll-like receptors triggering a rapid sterile inflammatory 101	
response (8, 9).  102	
SLRPs also function as complement modulators, both as activators and inhibitors 103	
(10). Both FMOD and OSAD interact with the globular head domain of C1q 104	
stimulating activation of the classical complement pathway (11). In contrast, both 105	
BGN and DCN bind primarily to the stalk region of C1q, inhibiting classical pathway 106	
activation, presumably through inhibition of C1s/C1r activity (11, 12). Additionally, 107	
both FMOD and OSAD capture C4BP and FH and therefore may limit complement 108	
activation at early stages of the classical pathway (11, 13). Whether these SLRPs 109	
interact with M. catarrhalis and alter complement activity and bacterial elimination is 110	
currently unknown and provided the motivation for the current study. 	  111	
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Materials and Methods 112	
Bacteria and culture conditions 113	
A list of bacterial strains used in this study is shown in Table 1. Moraxella 114	
catarrhalis clinical and laboratory strains, Haemophilus influenzae type b (Hib) strain 115	
RM804 and non-typeable H. influenzae (NTHi) strain 3655 were grown on chocolate 116	
agar plates for 24 h at 37 °C with 5 % CO2. Bacteria were subsequently streaked onto 117	
new chocolate agar plates for 6 h, scraped from plates, resuspended in 25 % (v/v) 118	
brain-heart infusion (BHI) broth/glycerol and stored in aliquots at - 80 °C. 119	
Pseudomonas aeruginosa ATCC27853 and KR601were grown in LB broth for 24 h 120	
at 37 °C with shaking.  121	
 122	
Proteins, antibodies and sera  123	
Human recombinant small leucine-rich proteoglycans (SLRPs) including 124	
fibromodulin (FMOD), osteoadherin (OSAD), biglycan (BGN), and decorin (DCN) 125	
were expressed with a hexa histidine tag from the pCEP4 vector in FreeStyle 293-F 126	
cells (Invitrogen) and purified using a similar protocol as described (14). The pCEP4 127	
vector containing fibromodulin (FMOD) was a gift from Dr. Sebastian Kalamajski 128	
(Uppsala University, Sweden) (15).  Briefly, FreeStyle 293 Expression Medium 129	
(Invitrogen) containing secreted SLRPs was collected and adjusted to 0.3 M NaCl and 130	
50 mM Tris-HCl, pH 8.0. Medium was then filtered through a 0.45-μm membrane, 131	
and concentrated using a 10-kDa cellulose membrane in a stirred ultrafiltration system 132	
(Amicon). The concentrated medium was then applied to a Ni2+-NTA column 133	
equilibrated with 50 mM Tris-HCl, pH 8.0 with 0.3 M NaCl. After washing with 5 134	
volumes of 50 mM Tris-HCl, pH 8.0, the protein in the column was eluted with a 135	
linear gradient of 0-500 mM imidazole in 50 mM Tris-HCl, pH 8.0. The eluted 136	
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proteins were analyzed by SDS-PAGE, dialyzed against PBS, and stored at -80°C in 137	
aliquots. SLRPs were confirmed by Western blotting with polyclonal rabbit anti-138	
bovine SLRPs Abs (homemade). The yield of protein from 1 liter of conditioned 139	
medium was 17 mg for FMOD, 10 mg for OSAD, 7 mg for BGN, and 14 mg for 140	
DCN. C4BP was purified from human plasma as described previously (16). 141	
Biotinylation of SLRPs was achieved using the EZ-LinkÔ Sulfo-NHS-LC-142	
Biotinylation kit (ThermoFisher) as per manufacturers’ instructions. Bovine serum 143	
albumin (A8806; Sigma) was used as control protein.  144	
    The following primary antibodies (Abs) were used for flow cytometric analysis of 145	
complement deposition on the surface of M. catarrhalis: polyclonal rabbit anti-human 146	
C1q (A0136, Dako), monoclonal mouse anti-human C4BP MK104 (homemade, (17)), 147	
mouse anti-human MAC (aE11, Hycult Biotech), and polyclonal rabbit anti-human 148	
C3d (A0063, Dako). Primary Abs were detected using fluorescently labeled 149	
secondary F(ab')2 goat anti-rabbit AF647 (A21246, Invitrogen) or goat anti-mouse 150	
AF647 (A21235, Invitrogen). For the detection of biotinylated proteins, streptavidin 151	
AF647 conjugate (S21374, ThermoFisher) was used.  152	
Normal human serum (NHS) was prepared from freshly drawn blood obtained 153	
form at least 10 healthy volunteers. Blood was allowed to clot for 30 min at room 154	
temperature and then incubated on ice for 1 h. Following two rounds of 155	
centrifugations at 700 x g, at 4 °C for 8 min, serum fractions were collect, pooled and 156	
stored immediately at - 80 °C. All healthy volunteers provided written informed 157	
consent according to the recommendations of the local ethical committee in Lund 158	
(permit 2017/582) and the Declaration of Helsinki (18). To prepare C4BP-depleted 159	
human serum (C4BP-dpl), freshly pooled human serum from four donors was passed 160	
through HiTrap affinity column coupled with the monoclonal C4BP antibody MK104. 161	
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Resulting serum samples were verified to be C4BP-depleted through ELISA analysis 162	
as described previously (19). Plasma-purified C1q was added (20 µg/mL) to restore 163	
C1q concentration to normal levels, as C1q is partially lost during C4BP depletion 164	
due to C1q binding to Ab-column. C4BP, purified from the serum from which it was 165	
depleted, was replenished at physiological concentrations (200 µg/mL).  166	
 167	
Binding of SLRPs to bacteria 168	
To screen binding of SLRPs to pathogenic bacteria, bacteria were grown on 169	
corresponding agar plates, washed, and suspended in PBS. After staining with 10 μM 170	
CFSE (Sigma-Aldrich), bacteria were resuspended into 1% (w/v) BSA/PBS. Bacterial 171	
suspension with 5 × 106 CFU in 50 μl was then mixed with an equal volume of 1% 172	
(w/v) BSA/PBS containing 100 μg/ml biotinylated FMOD (2.3 μM), OSAD (1.94 173	
μM), BGN (2.35 μM), and 200 μg/ml biotinylated DCN (4.94 μM). After an 174	
incubation at 37°C for 1 h, bacteria were centrifuged at 5000 × g for 10 min, washed 175	
once with 1% (w/v) BSA/PBS, and incubated with streptavidin-AF647 at room 176	
temperature. After incubation for 1 h in the dark, bacteria were centrifuged, washed 177	
once with 1% (w/v) BSA/PBS, and bound SLRPs on bacteria were detected using a 178	
Cyflow space flow cytometer (Partec). To examine binding of SLRPs to clinical 179	
isolates of bacteria, binding assays were performed as described above, and bound 180	
SLRPs on bacteria were detected in a 96-well plate using a CytoFLEX flow cytometer 181	
(Beckman Coulter). Bacteria directly incubated with Streptavidin Alexa Fluor 647 182	
conjugate were used as treatment control for background binding. CFSE+ bacteria 183	
were detected based on their fluorescence signal and a gating region was set to 184	
exclude debris. Geometric mean fluorescence intensity (gMFI) was used to determine 185	
amount of SLRPs binding to bacteria. 186	
	 9	
    To assess bacterial cell surface proteins responsible for binding of SLRPs, wild-187	
type (RH4) and isogenic mutants of uspA1, uspA2, mid and double mutant 188	
uspA1uspA2 and (Table 1) were grown, stained with CFSE and binding performed in 189	
identical fashion to the above conditions using a CytoFLEX flow cytometer.  190	
To assess direct binding of SLRPs with UspA2, MaxiSorp microtiter plates (Nunc) 191	
were coated overnight at 4 °C with recombinant UspA2 (0.14 μM; 10 μg/mL), cloned 192	
from M. catarrhalis strain RH4 and expressed in E. coli as described previously (20). 193	
Plates were washed three times with 300 μL of wash buffer (50 mM Tris, 150 mM 194	
NaCl, 0.1 % Tween 20, pH 8). Plates were blocked to prevent non-specific binding by 195	
using 250 μL of quench (wash buffer containing 3 % fish gelatin) and incubated at 196	
room temperature for 2 h. Plates were further washed three times in wash buffer and 197	
biotinylated SLRPs were added at increasing amounts (0.012 – 1.98 μM; 0.6 – 80 198	
μg/mL) in binding buffer (50 mM HEPES, 150 mM NaCl, 2 mM CaCl2, pH 7.4) for 199	
30 min at room temperature. Following incubation, plates were washed three times in 200	
wash buffer and wells were incubated with 50 μL streptavidin – HRP (1:200) in 201	
quench for 1 h at room temperature. Plates were further washed three times in wash 202	
buffer, developed using TMB substrate solution (ThermoFisher) and reaction stopped 203	
using 0.5 M H2SO4. Binding of SLRPs was detected using a Cytation 5 Cell Imaging 204	
plate reader (BioTek) at 450nm. 205	
 206	
Serum bactericidal assay 207	
Serum bactericidal assay was performed as described previously (21). Briefly, M. 208	
catarrhalis (2.5 x 105 CFU) were incubated with either 5 or 50 μg/mL SLRPs or BSA 209	
at 37 °C for 30 min in GVB++ buffer (5 mM veronal buffer pH 7.3, 0.1% (w/v) gelatin, 210	
140 mM NaCl, 1 mM MgCl2, and 0.15 mM CaCl2). Following incubation, 211	
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SLRPs/bacteria solution was washed in PBS or not and further incubated with pooled 212	
NHS to a final concentration of 10% (strain RH4) or 20% (strain Bc5) in GVB++ 213	
buffer. For calculation of bacterial survival, aliquots of bacteria were removed at time 214	
0 and following incubation at 37°C for 30 min, diluted in PBS and spread onto BHI 215	
agar for colony enumeration. Serum treated with complement C5 inhibitor OmCI (10 216	
μg/ml; 0.625 μM) (Swedish Orphan Biovitrum) (22) on ice for 30 min or compstatin 217	
CP40 (20 µM) (23) were used as serum controls. BSA at 50 μg/mL (0.75 μM), which 218	
has no effect on complement activation, was used as negative protein control. 219	
Bacteria were incubated with SLRPs alone at 37°C for 30 min in GVB++ buffer to 220	
determine whether SLRPs have antimicrobial activity. 221	
 222	
Complement deposition assay 223	
CFSE-labeled M. catarrhalis was incubated with pooled NHS in a 96-well plate in 224	
the presence of SLRPs, as described in the serum bactericidal assay. After incubation, 225	
bacteria were washed once with 1%-BSA/PBS, and deposited complement 226	
components were detected with primary Abs incubated at room temperature for 30 227	
min at a dilution of 1:1000 in 1%-BSA/PBS. Bacteria were centrifuged and washed 228	
once in 1%-BSA/PBS followed by fluorescently labeled secondary Abs staining for 229	
30 min at room temperature in the dark using a dilution of 1:1000. Bacteria were 230	
again centrifuged and washed once in 1%-BSA/PBS and finally resuspended in 150 231	
μL of 1%-BSA/PBS. Deposited complement components were assessed using a 232	
CytoFLEX flow cytometer (Beckman Coulter). Geometric mean fluorescence 233	
intensity (gMFI) was used to determine amount of complement deposition. Heat-234	
inactivated serum, primary isotype antibody and secondary antibody only controls 235	
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were used to assess specificity of antibodies used. Stained and unstained bacteria were 236	
used for gating bacteria and a minimum of 20,000 events was examined.  237	
 238	
Neutrophil bactericidal assays 239	
Human neutrophils were isolated using firstly HistopaqueÒ-1119 (Sigma) 240	
separation of peripheral venous blood drawn from healthy volunteers and secondly a 241	
Percoll-based gradient method as previously described (24). Neutrophils were 242	
resuspended in RPMI 1640 plus 10 mM HEPES and viability was assessed by trypan 243	
blue staining typically yielding greater than 95%. For neutrophil bactericidal assays, 244	
neutrophils (5 x 105) were incubated with M. catarrhalis (5 x 106 CFU) (MOI 10) in 245	
the presence of 200 μg/mL SLRPs (4.5 μM (FMOD), 3.9 μM (OSAD), 4.7 μM 246	
(BGN), 4.9 μM (DCN)) or BSA with either 5% OmCI-treated or compstatin-treated 247	
serum in a final volume of 300 μL. Plates were incubated at 37°C, 5% CO2 and at 248	
time 30 and 60 min neutrophils were lysed using 1 % saponin/PBS for 15 min on ice. 249	
Bacteria were diluted in PBS and plated onto BHI agar plates and incubated for 24 h 250	
at 37°C with 5% CO2. Colonies were counted and intra- and extracellular bacterial 251	
survival was assessed by dividing CFU at time 30 or 60 min by CFU at time 0.  252	
 253	
Statistical analysis 254	
A one-way or two-way ANOVA was used to examine the difference between 255	
experimental results (GraphPad Prism v7.0) where a p value <0.05 was considered to 256	
be statistically significant. The p values reported in figure legends represent the post-257	
hoc tests.	  258	
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Results 259	
SLRPs specifically bind M. catarrhalis  260	
 SLRPs have been shown to regulate various extracellular matrices and modulate 261	
cellular functions and innate immunity via interaction with cell surface receptors (7-262	
9). We previously reported that SLRPs FMOD, OSAD, BGN and DCN could regulate 263	
complement activity through interaction with C1q, C4BP and FH (11, 13). However, 264	
whether these SLRPs play a role in modulating innate immune responses directed 265	
against pathogenic bacteria remains unclear. To understand the role of SLRPs in 266	
innate immunity, we expressed recombinant human SLRPs in eukaryotic cells and 267	
purified them using affinity chromatography. The purified SLRPs were estimated 268	
with a purity of ³ 90% by SDS-PAGE under reducing conditions (Fig. 1A) and 269	
confirmed by Western blotting using our in-house rabbit anti-bovine SLPRs, which 270	
are highly similar to human SLRPs (Fig. 1B). Recombinant his-tagged FMOD, 271	
OSAD, BGN, and DCN are predicted be 44.0, 50.4, 40.6, and 38.7 kDa, respectively. 272	
However, all proteins are larger than the predicted molecular mass in SDS-PAGE gel 273	
due to glycosylation. Next, we determined the binding of biotinylated SLRPs to major 274	
Gram-negative bacterial species important in respiratory infections, namely 275	
Pseudomonas aeruginosa, Haemophilius influenzae and M. catarrhalis. We found 276	
that of these pathogens only M. catarrhalis (laboratory strains Bc5 and RH4) bound 277	
the four SLRPs (Fig. 1C-F). 278	
 279	
FMOD, OSAD and BGN enhance complement-mediated killing of M. catarrhalis 280	
As SLRPs can both regulate complement activity and bind M. catarrhalis, we 281	
aimed to determine whether SLRPs affect survival of M. catarrhalis in pooled normal 282	
human serum (NHS). We found that SLRPs FMOD, OSAD and BGN when 283	
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supplemented at 50µg/mL significantly decreased survival of both M. catarrhalis 284	
RH4 (Fig. 2A) and Bc5 (Fig. 2B) in NHS. Despite being not statistically significant, 285	
DCN led to a slight reduction in survival in the Bc5 strain compared to BSA, but no 286	
difference was observed in strain RH4, suggesting that DCN does not enhance 287	
complement-mediated killing of M. catarrhalis. Furthermore, inhibition of MAC 288	
formation by previous treatment of serum with the C5 inhibitor OmCI prevented 289	
killing of M. catarrhalis under any SLRP condition illustrating that SLRPs enhance 290	
killing through complement mediated lysis (Fig 2A-B). Lastly, no antimicrobial 291	
activity was observed when SLRPs were incubated with M. catarrhalis in GVB++ 292	
buffer in the absence of serum, confirming that the enhanced killing was mediated by 293	
complement. To verify that excess unbound SLRPs were not causing a by-stander 294	
complement activation effect and contributing to enhanced killing, we also measured 295	
the effect of washing bacteria following SLRP binding prior to incubation with serum 296	
(Fig. S1). As in the above results, a significant decrease in survival was observed for 297	
FMOD, OSAD and BGN but not DCN, indicating the SLRPs bound to the bacterial 298	
surface promoted enhanced bacterial killing in the presence of serum.  299	
 300	
SLRPs interact directly with UspA2/2H of M. catarrhalis 301	
M. catarrhalis interacts with human proteins via major surface proteins such as 302	
UspA1/A2, MID, and outer membrane porins such as OmpCD and Mha (4). Given 303	
that previous work has shown that UspA1, UspA2 and MID can interact with soluble 304	
extracellular matrix proteins we investigated the interaction of wild type (RH4) and 305	
isogenic mutants lacking the above surface proteins with biotinylated SLRPs through 306	
flow cytometry (Fig. 3A-D).  We found that deletion of the uspA2 gene resulted in a 307	
significant decrease in binding of all SLRPs in question highlighting the importance 308	
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of UspA2 as a ligand for SLRP binding. No difference in binding was observed with 309	
neither the uspA1 nor mid mutants.  310	
To further elucidate the interaction between SLRPs and M. catarrhalis we 311	
employed a direct biochemical binding assay using immobilized recombinant UspA2, 312	
derived from strain RH4, and increasing concentrations of biotinylated SLRPs and 313	
BSA (Fig. 3E-F). In accordance with our binding results above employing wild-type 314	
and uspA2 mutant, all four SLRPs bound UspA2, with the highest affinity observed 315	
for BGN (Kd = 89 ±11 nM), similar affinities seen for FMOD (Kd = 202 ±21 nM) 316	
and OSAD (Kd = 231 ±28 nM) and the lowest affinity seen for DCN (Kd = 293 ±32 317	
nM). 318	
 319	
SLRPs bind to the majority of clinical isolates of M. catarrhalis 320	
To determine the clinical relevance of M. catarrhalis interaction with SLRPs we 321	
evaluated the binding capacity of a panel of clinical isolates (n=16) to all four SLRPs 322	
(Fig. 4A-D). These clinical isolates were chosen based on their respective differences 323	
in the N- terminal sequence motif of the UspA2 protein, in order to capture a 324	
significant diversity of important clinical M. catarrhalis strains. This domain is 325	
classified into the different groups 2A, 2B, 2C and ‘nontypeable’ based on the domain 326	
distribution and sequence similarity (25). We found that the overwhelming majority 327	
of clinical isolates bound all four SLRPs whereby there was a general trend for 328	
increased binding in the order of FMOD ≥OSAD >BGN >DCN. However, isolates 329	
that express UspA2/2H with different N-terminal repeats of head domains showed no 330	
significant difference in binding of SLRPs (Fig. S2). 331	
 332	
 333	
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FMOD, OSAD and BGN increase C3b and MAC deposition by preventing C4BP 334	
binding to M. catarrhalis 335	
To further understand how SLRPs regulate complement leading to the enhanced 336	
serum sensitivity of M. catarrhalis, we measured deposition of complement 337	
components on the bacterial surface in the presence of SLRPs, BSA or no added 338	
protein, using flow cytometry. In agreement with decreased survival of M. catarrhalis 339	
in serum, FMOD, OSAD and BGN significantly increased C3b deposition compared 340	
to BSA (gray stars) whereas only OSAD significantly increased C3b deposition 341	
compared to no protein control (Fig. 5A). Next, we looked at MAC deposition 342	
following incubation for 20 min in serum, a shortened time to prevent significant 343	
lysis. Complementing the serum killing and C3b deposition results, FMOD, OSAD 344	
and BGN had significantly more MAC deposited on the bacterial surface compared to 345	
BSA or DCN (Fig. 5B).  346	
As acquisition of C4BP by M. catarrhalis is an efficient strategy to prevent 347	
complement-mediated lysis and is facilitated through interaction with UspA1 and 348	
UspA2 (6), with hypothesized that SLRPs FMOD, OSAD and BGN may 349	
competitively inhibit binding of C4BP and thus render M. catarrhalis more 350	
susceptible to serum killing. We measured C4BP binding following incubation in 351	
OmCI-treated serum and showed a significant decrease when bacteria were 352	
previously incubated with FMOD, OSAD and BGN, with again, no difference 353	
observed with DCN or BSA (Fig. 5C).  354	
To confirm our results that SLRPs inhibit binding of C4BP and thus disrupt a 355	
major immune evasive strategy of M. catarrhalis, we depleted C4BP from NHS using 356	
an anti-C4BP mAb MK104 coupled column, which interacts with high affinity to the 357	
α-chain complement control protein (CCP) domain 1 of C4BP (17). Depletion of 358	
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C4BP from NHS (C4BP-dpl) resulted in increased killing of M. catarrhalis RH4 359	
compared to NHS in the presence of both BSA and DCN (Fig. 5D). Increased 360	
survival comparable to NHS was observed following replenishment of purified C4BP 361	
to physiological levels (200 μg/mL) when BSA and DCN were present. In 362	
comparison, FMOD, OSAD and BGN enhanced serum bactericidal activity in NHS 363	
compared to both BSA and DCN as observed previously (Fig 2A-B). Importantly, no 364	
significant change in serum killing was observed between BSA/DCN and 365	
FMOD/OSAD/BGN in C4BP-dpl (Fig. 5D) confirming that prevention of C4BP 366	
binding by FMOD, OSAD and BGN to the bacterial surface is responsible for the 367	
increased complement-mediated killing of M. catarrhalis.  368	
 369	
OSAD and BGN enhance neutrophil killing of M. catarrhalis in a complement 370	
dependent and independent manner 371	
Neutrophils represent a critical phagocytic cell type in innate immunity, central to 372	
host defense against invading pathogens. Additionally, complement mediated 373	
opsonisation accelerates phagocytosis and removal of pathogenic bacteria. 374	
Considering that SLRP-bound bacteria had increased complement deposition in the 375	
presence of serum, we wanted to investigate whether this translated into increased 376	
killing in a neutrophil bactericidal assay. Interestingly, in the presence of human 377	
neutrophils and OmCI-treated serum, both OSAD and BGN significantly enhanced 378	
M. catarrhalis RH4 killing, observed at both 30 and 60 min incubation period (Fig. 379	
6A). Incubation with FMOD or DCN did not significantly increase bacterial killing 380	
compared to BSA. Next we wanted to investigate whether this enhanced neutrophil 381	
killing was dependent on complement opsonisation or whether SLRPs themselves 382	
could serve as mediators of enhanced neutrophil killing. Using OSAD and BGN, we 383	
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repeated the neutrophil bactericidal assays with either OmCI-treated serum (inhibiting 384	
complement at the C5 level) or compstatin-treated serum (inhibiting complement at 385	
the C3 level). At 30 min we observed only a decrease in bacterial survival in the 386	
OmCI-treated serum conditions and not in the presence of compstatin (Fig. 6B). 387	
Surprisingly, after 60 min we observed a statistically significant decrease in survival 388	
both with the OmCI- and compstatin-treated sera compared to BSA. This suggests 389	
that the main mechanism of SLRP-dependent enhanced neutrophil killing is via 390	
complement activation. After a prolonged incubation time, however, SLRPs promote 391	
a bactericidal killing effect in concert with neutrophils, which is independent of 392	
complement.  393	
As compstatin-treated serum still contains C1q, which can act as an opsonin and 394	
promote phagocytosis, and as previous work has shown that SLRPs can interact with 395	
C1q (11, 12), we investigated the binding of C1q from serum in the presence of 396	
SLRPs (Supp Fig. 3). We observed no difference in binding of C1q to the bacterial 397	
surface when bacteria were incubated with FMOD or DCN compared to BSA. In 398	
contrast, a significant reduction in C1q binding was shown when bacteria were bound 399	
with OSAD and BGN. Therefore, these results indicate that enhanced neutrophil 400	
killing under compstatin-treated serum conditions in the presence of OSAD and BGN 401	
was not due to increased C1q binding.	  402	
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Discussion  403	
M. catarrhalis causes significant morbidity in children and COPD patients, and is 404	
responsible for a plethora of respiratory infections and occasionally, systemic diseases 405	
(26). The exact molecular mechanisms governing M. catarrhalis pathogenicity are not 406	
fully understood. However, mounting evidence suggests that immune evasion, 407	
directed primarily at circumventing the complement system, is an essential feature of 408	
pathogenic strains (4-6, 14, 21, 27). Therefore, future treatment intervention directed 409	
at hampering complement inhibitor recruitment is a promising avenue of research. In 410	
this study, we highlight a novel antimicrobial role displayed by specific SLRPs, 411	
namely FMOD, OSAD and BGN and in detail revealed the molecular mechanisms 412	
resulting in enhanced innate immunity against M. catarrhalis.  413	
SLRPs such as BGN and DCN are considered bi-functional proteoglycans, acting 414	
both as central structural components of the ECM and danger-associated molecular 415	
patterns (DAMPs) stimulating immune reactions (28). SLRPs are abundantly present 416	
in the ECM and distributed in numerous tissues throughout the body (7). Previous 417	
immumohistochemical analysis has shown that BGN and DCN are expressed in the 418	
human lung and bronchial tissue (29-31). Furthermore, mining of the Human Protein 419	
Atlas (www.proteinatlas.org) (32), a genome-wide analysis of RNA and protein 420	
expression from samples representing major tissues and organs, confirmed the 421	
expression of all SLRPs used in this study in lung tissue. RNA expression data 422	
generated from 320 individual tissue samples showed that for this set of SLRPs, BGN 423	
and DCN had the highest expression, followed by FMOD with OSAD having the 424	
lowest expression (Suppl Fig 4). Combined, these expression data and previous 425	
immunohistochemical analysis indicate that these SLRPs are present in sites 426	
anatomically important for M. catarrhalis infection and therefore may play a role in 427	
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host innate immune defense. The exact concentrations of SLRPs present in human 428	
tissue and/or plasma are difficult to estimate. One reason for this is that SLRPs are 429	
present in higher concentrations following trauma, proteolysis of the ECM and under 430	
sterile and non-sterile inflammatory conditions. Previous work in the field has shown 431	
that both BGN and DCN expression is enhanced during experimental sepsis in murine 432	
models following LPS challenge (8, 9). Macrophages were observed to be the main 433	
secretory cell responsible for enhanced expression. Following stimulation with IL-1β 434	
and Il-6, macrophage increased BGN secretion, which in turn induced expression of 435	
TNFα and MIP-2, contributing to the overall pro-inflammatory environment and 436	
increased SLRP expression (8). Furthermore, DCN expression has been shown to be 437	
higher in cohorts of septic patients compared to healthy controls (9). In this study 438	
DCN concentration in plasma were estimated to be at 10 ng/mL in septic patients. 439	
Previous studies by this group also estimated another SLRP, PRELP, to be at a similar 440	
range present in bronchoalveolar lavage fluid (14). It is tempting to speculate that 441	
during infection and particularly sepsis, SLRP expression is increased as a result of 442	
secretion of pro-inflammatory cytokines stimulating macrophages and other immune 443	
and non-immune cells while at the same time the highly inflamed environment 444	
contributes to increased SLRP proteolysis from the ECM. Therefore during infection 445	
the local concentration of SLRPs may be higher than the surrounding environment 446	
which could influence complement and innate immune activity and bacterial survival. 447	
Of the three main Gram-negative respiratory pathogens screened in this study, only 448	
M. catarrhalis was bound by SLRPs. M. catarrhalis expresses numerous surface 449	
proteins, which bind an array of ECM proteins, plasma and complement components 450	
permitting colonization and evasion of the host innate and adaptive immunity (4, 26). 451	
The major surface proteins of M. catarrhalis are the UspA1 and UspA2/2H. Both 452	
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UspA1 and A2/2H interact with C4BP, however UspA2/2H is more strongly 453	
expressed than UspA1 and therefore plays a more prominent role in C4BP binding 454	
and in conferring a complement resistant phenotype (6). Through mutational analysis 455	
we determined that all four SLRPs bound to M. catarrhalis predominantly through 456	
UspA2/2H. This suggested that SLRP binding to UspA2/2H could competitively 457	
inhibit C4BP binding resulting in reduced complement inhibition. Using flow 458	
cytometry we illustrated that prior binding of FMOD, OSAD, BGN but not DCN to 459	
M. catarrhalis effective reduced C4BP binding thus explaining the increased serum 460	
sensitivity.  461	
Given the similarity between BGN and DCN it is surprising that BGN and not 462	
DCN competitively inhibits C4BP binding. Both BGN and DCN are members of the 463	
class I SLRP family, possessing significant homology at both the protein and genetic 464	
level. BGN contains two N-terminal tissue-specific chondroitin/dermatan sulfate side 465	
chains whereas DCN contains one, and both differ in the pattern and level of 466	
glycosylation (7). These differences permit both SLRPs to perform different tasks in 467	
terms of ECM maintenance and cell signaling and possibly binding to different 468	
regions of UspA2, resulting in differential inhibition of C4BP. Our results show that 469	
M. catarrhalis can bind both DCN and C4BP simultaneously. UspA2 is a trimeric 470	
autotransporter adhesin, which interacts with C4BP specifically at the CCP2, CCP5 471	
and CCP7 domains (6).  UspA2 is composed of a globular head and stalk domain and 472	
therefore it is feasible that DCN but not the other SLRPs bind to specific regions 473	
within UspA2 that are not required for C4BP binding. Future biochemical studies are 474	
required to fully confirm this hypothesis.  475	
Incubation of bacteria with SLRPs in the presence of serum resulted in significant 476	
opsonisation with C3b/iC3b (Fig. 5A). As these opsonins are recognized by 477	
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complement receptors present on neutrophils we wished to examine where this 478	
resulted in enhanced neutrophil bactericidal killing. Here we observed that only 479	
OSAD and BGN effectively increased neutrophil killing of M. catarrhalis but not 480	
FMOD or DCN. This was surprising considering that FMOD enhanced C3b 481	
opsonisation in the presence of serum.  Therefore, we checked whether this enhanced 482	
neutrophil killing was independent of complement by using compstatin-treated serum, 483	
effectively blocking complement at the C3 level. We observed that the majority of the 484	
neutrophil killing was complement (opsonisation) mediated (Fig. 6A). However with 485	
prolonged incubation both OSAD and BGN enhanced killing in a complement 486	
(opsonisation) independent manner. It is known that certain ECM proteins such as the 487	
SLRP lumican can enhance phagocytosis by interacting with both bacteria and 488	
phagocytes via surface expressed integrins (33). Additionally, it has been shown that 489	
other SLRPs such as BGN and DCN can bind to toll-like receptors expressed on 490	
professional phagocytes and induce a pro-inflammatory response (8, 9). Two 491	
questions arise that require future molecular dissection: 1) Can FMOD and OSAD 492	
interact with professional phagocytes and induce an immune response analogous to 493	
BGN and DCN and 2) can the SLRPs in question mediate an interaction between 494	
bacteria and phagocytes which facilitates enhanced phagocytosis and subsequent 495	
killing. As such future molecular characterization is underway to elucidate fully the 496	
mechanisms of SLRPs mediated neutrophil bactericidal activity.  497	
Recent work by our lab has shown that respiratory pathogens such as M. 498	
catarrhalis can interact with ECM components whereby two opposing scenarios may 499	
result, namely attenuated or enhanced complement activity. M. catarrhalis interacts 500	
with cartilage oligomeric matrix protein (COMP) preventing complement deposition 501	
and interfering with complement-independent phagocytosis, enhancing survival (21). 502	
	 22	
Conversely, M. catarrhalis can be bound by the SLRP, Proline/arginine-rich end 503	
leucine-rich repeat protein (PRELP), which disrupts C4BP binding, significantly 504	
augmenting complement-mediated lysis and neutrophil killing (14). To this complex 505	
interaction between complement, M. catarrhalis and ECM components we introduce 506	
the newfound antibacterial role of FMOD, OSAD and BGN, which through 507	
interaction with the surface expressed UspA2/2H and in concert with complement, 508	
accelerate the eradication of an important respiratory pathogen. Finally, the 509	
elucidation of the molecular basis for SLRP-mediated enhanced killing may provide 510	
novel research avenues to devise therapies to treat infection. 	  511	
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Table 1: List of strains used in this study 536	
Clinical isolate / strain Description Reference 
Moraxella catarrhalis   
KR529 Clinical isolate (14) 
KR485 Clinical isolate (14) 
O35E Clinical isolate (14) 
KR516 Clinical isolate (14) 
KR531 Clinical isolate (14) 
KR540 Clinical isolate (14) 
KR503 Clinical isolate (14) 
KR488 Clinical isolate (14) 
KR509 Clinical isolate (14) 
KR484 Clinical isolate (14) 
KR480 Clinical isolate (14) 
BBH18 Clinical isolate (14) 
O46E Clinical isolate (14) 
CCUG353 Clinical isolate (14) 
KR483 Clinical isolate (14) 
Bc5 Laboratory strain (34) 
RH4 Laboratory strain (35) 
RH4DuspA1 RH4 devoid of ubiquitous surface protein A1 (6) 
RH4DuspA2 RH4 devoid of ubiquitous surface protein A2 (6) 
RH4DuspA1DuspA2 RH4 devoid of both ubiquitous surface protein A1 
and A2 
(6) 
RH4Dmid RH4 devoid of immunoglobulin D (IgD)-binding 
protein (MID) 
(36) 
Pseudomonas 
aeruginosa 
  
ATCC27853 Laboratory strain  ATCC 
KR601 Clinical isolate This study 
Haemophilus 
influenzae 
  
type b strain RM804 Clinical isolate, capsule-deficient  (37) 
non-typeable (NTHi) 
strain  3655 
Clinical isolate, encapsulated  CCUG 
Abbreviations: CCUG; Culture Collection University of Gothenburg, ATCC; 537	
American Type Culture Collection 538	 	  539	
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Figure legends 540	
Figure 1. Small leucine-rich proteoglycans (SLRPs) interact with M. catarrhalis 541	
Recombinant human SLRPs detected by A) reducing SDS-PAGE (5 μg of each 542	
protein) and B) Western blotting (0.5 μg). Biotinylated C) FMOD, D) OSAD, E) 543	
BGN and F) DCN were incubated with major respiratory pathogens P. aeruginosa, H. 544	
influenzae and M. catarrhalis and bound SLRPs were detected with fluorescently 545	
labeled streptavidin by measuring fluorescence intensity using a Cyflow space flow 546	
cytometer (Partec). Mean values and standard deviation (SD) of at least 3 individual 547	
experiments are shown. Statistical differences were calculated using a one-way 548	
ANOVA analysis with Bonferroni’s post-test in comparison to control without 549	
SLRPs. ** p < 0.01, *** p < 0.001,  **** p < 0.0001.  550	
 551	
Figure 2. FMOD, OSAD and BGN enhance serum killing of M. catarrhalis  552	
Bacterial survival in human serum was defined as the ratio (%) of the colony-forming 553	
units (CFU) at 30 min to time 0. Error bars represent SD of three independent 554	
experiments. Serum treated by C5 inhibitor OmCI was used as serum control, and 50 555	
µg/ml BSA was used as a negative protein control. Statistical differences were 556	
calculated using a one-way ANOVA with Dunnett’s post-test versus bacteria without 557	
SLRPs. * p < 0.05, ** p < 0.01, *** p < 0.001,  **** p < 0.0001.   558	
 559	
Figure 3. SLRPs interact directly with UspA2/2H of M. catarrhalis  560	
Biotinylated SLRPs were incubated with M. catarrhalis mutants devoid of selected 561	
surface proteins UspA1, UspA2/2H, and MID that interact with various host proteins. 562	
Bound SLRPs were detected with fluorescently labeled streptavidin by measuring 563	
fluorescence intensity using a CytoFLEX flow cytometer (Beckman Coulter). 564	
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UspA2/2H mutant showed significantly reduced binding of all SLRPs (A-D). 565	
Biotinylated SLRPs E) (FMOD and OSAD) and F) (BGN and DCN) bind 566	
immobilized recombinant UspA2 with differing affinities. Error bars represent SD of 567	
three independent experiments. Statistical differences were calculated using a one-568	
way ANOVA with Dunnett’s posttest versus wild type (RH4) bacteria. ** p < 0.01, 569	
*** p < 0.001, **** p < 0.0001.  570	
 571	
Figure 4. SLRPs bind to M. catarrhalis clinical isolates expressing UspA2/2H  572	
The highly diverse head domains of UspA2/2H are classified into N-terminal repeats 573	
(NTER) 2A, 2B, 2C, and 2H, and non-typeable. All tested clinical strains bound 574	
SLRPs at varying degrees. Negative control consisted of bacterial straining with 575	
Streptavidin Alexa Fluor 647 in the absence of biotinylated proteins.  Error bars 576	
represent the SD of three individual experiments.  577	
 578	
Figure 5. FMOD, OSAD and BGN increase complement deposition through 579	
inhibition of C4BP binding 580	
 Deposition of complement components A) C3b B) MAC and C) C4BP on M. 581	
catarrhalis RH4 was analyzed using flow cytometry. D) Bacterial survival in 5 % 582	
C4BP depleted sera (C4BP dpl) with matched survival in 5 % NHS and C4BP dpl 583	
replenished with C4BP (C4BP dpl + C4BP) at physiological concentrations. Error 584	
bars represent SD of three (A-C) and 5 (D) independent experiments. Serum treated 585	
by C5 inhibitor OmCI or heat-inactivated was used as serum control, and BSA was 586	
used as a negative protein control. Grey stars (BSA) and black starts (without protein 587	
w/o) indicate statistical calculations using a one-way ANOVA with Dunnett’s post-588	
test. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, ns, not significant. 589	
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Figure 6. SLRPs OSAD and BGN enhance neutrophil killing of M. catarrhalis 590	
Human neutrophils were incubated with M. catarrhalis RH4 in the presence of A) 591	
OmCI-treated serum and SLRPs or BSA or B) OmCI or compstatin-reated serum and 592	
OSAD, BGN or BSA for 30 or 60 min at 37°C and 5%CO2. Following incubation 593	
total viable bacteria was enumerated following lysis of neutrophils and bacterial 594	
survival was calculated by diving CFU at time 30 or 60 with that of time 0. Graphs 595	
are presented as the mean and SD of 5 independent experiments and analyzed using a 596	
two-way ANOVA with Bonferroni post-hoc tests comparing SLRP/BSA condition to 597	
that of no protein control (without, w/o) A) or SLRPs to BSA control B). * p < 0.05, 598	
** p < 0.01, *** p < 0.001, **** p < 0.0001. 599	
 600	
Abbreviations: BHI, brain-heart infusion; BGN, biglycan; C4BP, C4b-binding 601	
protein; CCP, complement control protein; DCN, decorin; dpl, depleted serum; FH, 602	
factor H; FMOD, fibromodulin; MAC, membrane attack complex; NHS, normal 603	
human serum; NTER, N-terminal repeat; OSAD, osteoadherin; SLRP, short leucine-604	
rich proteoglycan; Usp, ubiquitous surface protein.  605	
 606	
 607	
 608	
 609	
 610	
 611	
 612	
 613	
 614	
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SDS-PAGE Western Blot
Figure 1. Small leucine-rich proteoglycans (SLRPs) interact with M. catarrhalis 
Recombinant human SLRPs detected by A) SDS-PAGE and B) Western blotting. 5 µg of 
each protein was loaded into wells for reducing SDS-PAGE, and 0.5 µg for Western blotting. 
Biotinylated C) FMOD, D) OSAD, E) BGN and F) DCN were incubated with major 
respiratroy pathogens P. aeruginosa, H. influenzae and M. catarrhalis and bound SLRPs 
were detected with fluorescently labeled streptavidin by measuring fluorescence intensity. 
Standard error of the mean (SEM) of at least  3 individual experiments is shown. Statistical 
differences were calculated using a one-way ANOVA analysis with Bonferroni’s posttest in 
comparison to control without SLRPs. ** p < 0.01, *** p < 0.001,  **** p < 0.0001. 
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Figure 2. SLRPs enhance serum killing of M. catarrhalis 
Bacterial survival in human serum was defined as the ratio (%) of the colony-forming units 
(CFU) at 30 min to time 0. Error bars represent SD of three independent experiments. 
Serum treated by C5 inhibitor OmCI was used as serum control, and 50 µg/ml BSA was 
used as a negative protein control. * p < 0.05, ** p < 0.01, *** p < 0.001,  **** p < 0.0001 
versus w/o SLRPs, one-way ANOVA with Dunnett’s posttest. 
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Figure 4. SLRPs bind to M. catarrhalis clinical isolates expressing UspA2/2H. The highly 
diverse head domains of UspA2/2H are classified into N-terminal repeats (NTER) 2A, 2B, 2C, 
and 2H, and non-typeable. All tested clinical strains bound SLRPs at varying degrees. Negative 
control consisted of bacterial straining with Streptavidin Alexa Fluor 647 in the absence of 
biotinylated proteins.  Error bars represent the SD of three individual experiments.
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Figure 5
Figure 5. FMOD, OSAD and BGN increase complement deposition through inhibition of C4BP binding
Deposition of complement components A) C3b B) MAC and C) C4BP on M. catarrhalis was analyzed using 
flow cytometry. D) Bacterial survival in 5 % C4BP depleted sera (C4BP dpl) with matched survival in 5 % 
NHS and C4BP dpl replenished with C4BP (C4BP dpl + C4BP) at physiological concentrations. Error bars 
represent SD of three (A-C) and 5 (D) independent experiments. Serum treated by C5 inhibitor OmCI or heat-
inactivated was used as serum control, and BSA was used as a negative protein control. Grey stars (BSA) and 
black starts (without protein w/o) indicate statistical calculations using a one-way ANOVA with Dunnett’s 
posttest. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, ns, not significant.
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Figure 6. SLRPs OSAD and BGN enhance neutrophil killing of M. catarrhalis
Human neutrophils were incubated with M. catarrhalis in the presence of A) 
OmCI-treated serum and SLRPs or BSA or B) OmCI or compstatin-reated serum 
and OSAD, BGN or BSA for 30 or 60 min at 37°C and 5%CO2. Following 
incubation total viable bacteria was enumerated following lysis of neutrophils and 
bacterial survival was calculated by diving CFU at time 30 or 60 with that of time 
0. Graphs are presented as the mean and SD of 5 independent experiments and 
analyzed using a two-way ANOVA with Bonferroni post hoc tests comparing 
SLRP/BSA condition to that of no protein control (without, w/o) A) or SLRPs to 
BSA control B). * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
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Supplementary Figure 1
Figure S1. Removal of excess SLRPs does not impede serum 
killing
Serum killing of strain RH4 following washing of bacterial-
SLRP solution after 30 min incubation, removing unbound 
SLRPs. Survival is calculated as the percentage of colony-
forming units (CFU) at 30 min to time 0. Error bars represent 
SD of three independent experiments. 50 µg/ml BSA was used 
as a negative protein control. Statistical differences were 
calculated using a one-way ANOVA with Dunnett’s posttest 
versus bacteria without SLRPs. **** p < 0.0001.
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Supplementary Figure 2
Figure S2. M. catarrhalis isolates of different N-terminal repeats (NTER) of 
head domains bind SLRPs in similar fashion 
The SLRP binding capacities of M. catarrhalis clinical isolates expressing 
UspA2/2H were grouped according to their N-terminal repeat (NTER) domain; 2A, 
2B, 2C, and 2H, and non-typeable. No significant difference in binding to SLRPs 
was observed between NTER groups and all NTER groups bound SLRPs in a 
statistically significant manner. Statistical differences were calculated using a one-
way ANOVA with Dunnett’s posttest. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p 
< 0.0001. 
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Supplementary Figure 3
Figure S3. OSAD and BGN significantly reduce C1q binding on M. 
catarrhalis
Deposition of C1q on the surface of M. catarrhalis was analysed by flow 
cytometry using 1% OmCI-treated serum. Data illustrates the mean and 
SD of three independent experiments. Statistical differences were 
calculated using a one-way ANOVA with Dunnett’s posttest. * p < 0.05, 
**** p < 0.0001. 
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Supplementary Figure 4
Figure S4. SLRP RNA expression from lung 
tissue 
RNA expression of SLRPs from lung tissue 
samples (n=320) adapted from the Human Protein 
Atlas program (www.proteinatlas.org) (32). RNA 
sequencing data is reported in reads per kilobase 
per million mapped reads (RPKM). 
